Press Releases
Samsung Biologics hosts Annual General Meeting of Shareholders
Samsung Biologics hosts Annual General Meeting of Shareholders
Samsung Biologics hosted its 14th Annual General Meeting of Shareholders.
The shareholders approved all agenda items as proposed, including financial statements as well as appointments of internal and external board directors and an audit committee member.
“We thank our shareholders for continued trust and confidence in the company,” said John Rim, CEO and President of Samsung Biologics. “We will open a new era of growth with Bio Campus II and further build on our capabilities to deliver our full potential, maximizing client and stakeholder satisfaction.”
Samsung Biologics expects to maintain positive growth momentum this year through quality and operational excellence. The company also continues to invest in capacity, portfolio, and geographical expansion.
Plant 5, the first facility of Bio Campus II, will be operational next month, adding fresh capacity of 180,000 liters. Samsung Biologics has also launched ADC services at its dedicated, standalone facility. Earlier this year, the company opened a sales office in Tokyo to better support clients in Japan and the wider APAC region.
Detailed information on the Annual General Meeting is available here.
Samsung Biologics hosts Annual General Meeting of Shareholders
Samsung Biologics hosted its 14th Annual General Meeting of Shareholders.
The shareholders approved all agenda items as proposed, including financial statements as well as appointments of internal and external board directors and an audit committee member.
“We thank our shareholders for continued trust and confidence in the company,” said John Rim, CEO and President of Samsung Biologics. “We will open a new era of growth with Bio Campus II and further build on our capabilities to deliver our full potential, maximizing client and stakeholder satisfaction.”
Samsung Biologics expects to maintain positive growth momentum this year through quality and operational excellence. The company also continues to invest in capacity, portfolio, and geographical expansion.
Plant 5, the first facility of Bio Campus II, will be operational next month, adding fresh capacity of 180,000 liters. Samsung Biologics has also launched ADC services at its dedicated, standalone facility. Earlier this year, the company opened a sales office in Tokyo to better support clients in Japan and the wider APAC region.
Detailed information on the Annual General Meeting is available here.